Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.

ABSTRACT: This analysis from the multicenter, open-label, phase 3 BFORE trial reports efficacy and safety of bosutinib in patients with newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML) after five years' follow-up. Patients were randomized to 400-mg once-daily bosutinib (n = 268) or imatinib (n = 268; three untreated). At study completion, 59.7% of bosutinib- and 58.1% of imatinib-treated patients remained on study treatment. Median duration of treatment and time on study was 55 months in both groups. Cumulative major molecular response (MMR) rate by 5 years was higher with bosutinib versus imatinib (73.9% vs. 64.6%; odds ratio, 1.57 [95% CI, 1.08-2.28]), as were cumulative MR⁴ (58.2% vs. 48.1%; 1.50 [1.07-2.12]) and MR^4.5 (47.4% vs. 36.6%; 1.57 [1.11-2.22]) rat

SUBMITTER: Brummendorf TH 

PROVIDER: S-EPMC9252917 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature